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Abstract
Introduction The S100A7 (psoriasin) gene is highly expressed
in ductal carcinoma in situ (DCIS) of the breast and can be
downregulated in invasive carcinoma. Persistent S100A7
expression in invasive carcinoma is associated with a worse
prognosis, and this effect may be mediated in part through
interaction with the multifunctional cell signaling protein Jab1.
Methods In order to investigate the relationship between
S100A7 and progression from DCIS to invasive carcinoma, we
studied S100A7 expression in 136 patients with DCIS
(including 46 patients with associated invasive carcinoma) by
immunohistochemistry.
Results S100A7 expression was present in 63 out of 136
(46%) of DCIS lesions and was associated with estrogen
receptor negative status (P = 0.0002), higher nuclear grade (P
< 0.0001), necrosis (P  < 0.0001) and inflammation (P  <
0.0001). S100A7 status was no different between DCIS with
and DCIS without an invasive component, but higher levels of
S100A7 were present in DCIS associated with invasive
carcinoma (P < 0.004). Analysis of a subset of cases showed
that S100A7 expression was also associated with an increase
in nuclear Jab1 (n = 43; P = 0.0019) and reduced p27kip1 (n =
47; P = 0.0168). In cases of DCIS associated with invasive
carcinoma, there was also a significant reduction in S100A7
between in situ and invasive components (n = 46; P < 0.0001).
In pure DCIS cases treated by local excision, there was no
difference in frequency of S100A7 expression between patients
with recurrence of DCIS (n = 9) and those without (n = 36).
Conclusion The findings reported here suggest that, although
S100A7 may not be a marker for recurrence of DCIS, it is
associated with poor prognostic markers in DCIS and may
influence progression of breast carcinoma through its
interaction with and influence on Jab1.
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Introduction
We previously identified S100A7 (psoriasin) as a gene that
is expressed within preinvasive ductal carcinoma in situ
(DCIS) and that can be downregulated in invasive carcinoma
[1]. Later studies confirmed this observation and revealed
that S100A7 is among the most highly expressed genes in
DCIS [2,3] relative to both normal tissue and invasive carci-
noma. A similar pattern of expression is also seen in relation
to skin tumorigenesis, in which S100A7 is highly expressed
in preinvasive squamous cell carcinoma and is often down-
regulated in the adjacent invasive component [4].
We have now identified a potential functional relationship
between S100A7 and tumor progression, and a mecha-
nism of action through an interaction with the multifunc-
tional intracellular signaling protein Jab1 (c-jun activation
domain binding protein 1) [5,6]. Overexpression of
S100A7 in a breast cancer cell line is associated with
increased malignancy and with several changes in gene
expression that are compatible with an alteration in Jab1
activity [7]. The latter include a relative increase in nuclear
Jab1 and a decrease in the levels of the cell cycle inhibitor
p27kip1 [7,8].
DCIS = ductal carcinoma in situ; ER = oestrogen receptor; IHC = immunohistochemistry; Jab2 = c-jun activation domain binding protein 1.Breast Cancer Research    Vol 6 No 4    Emberley et al.
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Expression of S100A7 has been found to be highest in
DCIS but only small numbers of cases have been examined
[1-3]. S100A7 is also expressed in some invasive breast
tumors [2,9], in which S100A7 is associated with poor
prognostic factors and with poor outcome [7]. In the
present study, our aim was to determine the frequency of
expression of S100A7 in a large series of DCIS patients,
and its relationships to Jab1 and p27kip1 expression and to
progression and clinical outcome in DCIS.
Methods
Tissue specimens
Cases of pure DCIS of the breast were selected by review
of breast surgical resections that were done from 1981 to
1999 at the Health Sciences Centre and St. Boniface Hos-
pitals, Winnipeg, Manitoba. Cases of DCIS associated with
invasive carcinoma were selected from the Manitoba
Breast Tumor Bank [10], which operates with approval
from the Research Ethics Board of the Faculty of Medicine,
University of Manitoba. A total of 90 patients with pure
DCIS and 46 patients with DCIS associated with invasive
carcinoma were identified. The histologic nuclear grade
was determined according to the criteria for the Van Nuys
grading system [11]. The presence of intraductal necrosis,
defined as nuclear and eosinophilic debris, was evaluated
in hematoxylin–eosin stained sections by light microscopy,
and the percentage of ducts exhibiting necrosis was esti-
mated semiquantitatively. Periductal inflammation was
assessed semiquantitatively as low (absent or very sparse
inflammatory cells), high (marked inflammation surrounding
over 50% of the ducts), or intermediate. Estrogen receptor
(ER) status was determined by immunohistochemistry
(IHC) analysis, as described below.
The clinical/pathologic features of the entire series are
shown in Table 1. Among the cases of DCIS that had no
invasive carcinoma, the primary surgical treatment was
local excision in 45 patients and mastectomy in the other
45 patients. Amongst the former group, 27 patients had
surgery alone, 18 patients received adjuvant local radiation
therapy, and 11 received adjuvant hormone therapy. Clini-
cal follow-up data for the 45 patients treated by local exci-
sion were obtained from chart review and search of the
Manitoba Cancer Registry. Recurrence in the same breast
occurred in nine patients (in eight as DCIS and in one as
DCIS with microinvasive carcinoma) 9–50 months after ini-
tial diagnosis. For those cases with no recurrence the
median follow-up period was 66 months (range 23–184
months).
Immunohistochemistry
Serial sections (5 µm thick) were cut from a representative
formalin-fixed, paraffin-embedded archival tissue block from
each tumor. Immunohistochemical staining for S100A7, ER,
Jab1, and p27kip1 was performed as previously described
[7] but using an automated tissue immunostainer (Ventana
Medical Systems, Phoenix, AZ, USA) and DAB immunohis-
tochemistry kit (ABC method; Ventana Medical Systems).
Briefly, the staining protocol was set to the 'extended cell
conditioning' procedure, followed by 12 hours of incubation
with primary antibody before incubation with secondary
antibody and detection. Concentrations and sources of the
primary antibodies were 1:1000 for S100A7 [12], 1:50 for
ER (6F11; Novocastra Laboratories Ltd, distributed by Vec-
tor Laboratories (Canada) Inc., Burlington, Ontario, Can-
ada), 1:200 for Jab1 (FL-334; Santa Cruz Biotechnologies
Inc., Santa Cruz, CA., USA), and 1:1000 for p27kip1 (Clone
Table 1
Clinical/pathological features and frequency of S100A7 expression in ductal carcinoma in situ
Clinical/pathological features DCIS- DCIS+ All DCIS
n S100A7+ Pn S100A7+ Pn S100A7+ P
ER Negative 23 83% <0.0001 29 52% 0.76 (NS) 52 65% 0.0005
Positive 67 30% 17 53% 84 35%
Grade Low 34 15% <0.0001 9 11% 0.0041 43 14% <0.0001
Moderate 32 47% 19 47% 51 47%
High 24 79% 18 78% 42 79%
Necrosis Negative 47 23% <0.0001 15 20% 0.0024 q 23% <0.0001
Positive 43 65% 31 68% 74 66%
Inflammation Low 47 26% 0.0017 15 27% 0.054 (NS) 62 26% <0.0001
Moderate 26 62% 16 63% 42 62%
High 17 65% 15 67% 32 66%
P values were calculated using χ2 tests. DCIS-, pure ductal carcinoma in situ; DCIS+, DCIS associated with invasive carcinoma; ER, estrogen 
receptor; NS, not significant; S100A7+, proportion of S100A7 positive cases.Available online http://breast-cancer-research.com/content/6/4/R308
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57; Becton-Dickinson, BD Biosciences Canada, Missis-
sauga, Ontario). Known positive control breast tissues were
included with each staining batch to confirm that compara-
ble staining intensities existed between batches, and nor-
mal breast tissue within the sections served as additional
controls for Jab1, ER, and p27kip1.
Assessment of S100A7, ER, Jab1, and p27kip1 staining
IHC results for all genes were assessed by light micros-
copy performed by a pathologist (PHW) independently of
the pathologic assessment... The intraobserver variability in
IHC scoring for S100A7 was tested by comparison of IHC
scores from two independent sessions, and confirmed a
high degree of reproducibility (Spearman test r = 0.93; P <
0.0001). Levels of expression of S100A7, p27kip1, and
Jab1 proteins (both nuclear and cytoplasmic staining was
assessed separately for each) and ER protein (nuclear
staining only was assessed) were all determined by scoring
the intensity (0 = no staining, 1 = weak staining, 2 = mod-
erate staining, and 3 = strong staining) and the percentage
of neoplastic epithelial cells exhibiting staining within the
tissue section. The product of the intensity and the percent-
age was determined to provide a final, semiquantitative
immunostaining score (IHC scores, ranging from 0 to 300).
For S100A7 an IHC score greater than 0 was regarded as
positive (because we previously showed that this cut-point
can divide invasive carcinomas into good and poor out-
come subgroups [12], and S100A7 protein can be
secreted and so it is theoretically possible that expression
in a single cell might influence a wider group of tumor cells).
Among S100A7-positive cases, the lower 25th percentile
of expression corresponded to an IHC score of 1–9 and
the upper 75th percentile corresponded to an IHC score of
100 or greater. On this basis, IHC scores of 1–9, 10–99,
and 100 or geater were regarded as low, intermediate, and
high expression. For ER an IHC score greater than 10 was
regarded as positive (equivalent to the clinically validated
cut-point in similar IHC scoring systems).
Statistical analysis
Statistical analysis was performed with Prism Graphpad
software (Graphpad Prism v4.00, Graphpad software, San
Diego, CA, USA) and using Spearman correlation, χ2 test,
t-test and Wilcoxon rank sum tests as appropriate. P <
0.05 was considered statistically significant.
Results
Evaluation of S100A7 and pathologic features within 
ductal carcinoma in situ
In the entire series of 136 cases of DCIS studied by IHC,
63 out of 136 (46%) of DCIS lesions expressed S100A7.
The S100A7 IHC scores ranged from 0 to 270 (mean ±
standard deviation 28 ± 62; median 0). S100A7 expres-
sion was high in 16 cases, intermediate in 34 cases, and
low in 13 cases. In all positive cases the predominant cel-
lular localization for expression was cytoplasmic. S100A7
nuclear expression was infrequent, being present only in 13
out of 63 (21%) of S100A7-positive cases, and was not
significantly associated with any specific clinical/patho-
logic factors. Expression was restricted to epithelial tumor
cells and was not observed in adjacent normal ducts or lob-
ules, as we described previously [9]. Representative exam-
ples of S100A7 staining are illustrated in Fig. 1.
S100A7 expression in the entire series correlated with high
nuclear grade (r = 0.57; P < 0.0001, Spearman test), low
ER levels (r = -0.38; P < 0.0001), extent of necrosis (r =
0.48; P < 0.0001), and the presence of inflammation (r =
0.39; P < 0.0001). Similarly, when S100A7 and prognos-
tic factors were considered as categorical variables,
S100A7 expression was also significantly associated with
ER-negative status (P = 0.0005), high grade, and presence
of necrosis and inflammation (P < 0.0001, χ2 test; Table 1).
In subgroup analysis S100A7 was expressed in 25 out of
31 (81%) high-grade/ER-negative/necrosis-positive DCIS
cases, as compared with six out of 40 (15%) low-grade/
Figure 1
S100A7, Jab1, and p27kip1 expression in DCIS detected by  immunohistochemistry S100A7, Jab1, and p27kip1 expression in DCIS detected by immunohis-
tochemistry. The upper panels show high levels of S100A7 expression 
in (a) pure ductal carcinoma in situ (DCIS) and in (b) DCIS associated 
with invasive carcinoma. Note the reduced expression in the invasive 
component (panel b, right) relative to the in situ component (panel b, 
left). The middle panels show Jab1 expression in (c) S100A7-negative 
and (d) S100A7-positive DCIS cases. The lower panels show (e) high 
and (f) low p27kip1 expression in the same two DCIS cases.Breast Cancer Research    Vol 6 No 4    Emberley et al.
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ER-positive/necrosis-negative DCIS cases (P < 0.0001, χ2
test).
Relationship between S100A7, Jab1, and p27kip1
Expression of Jab1 and p27kip1 was also assessed in DCIS
in a subgroup of 47 cases in which there was sufficient
material available. These included 26 cases of pure DCIS
and 21 cases of DCIS associated with invasive carcinoma.
Reduced expression of p27kip1 was associated with high
grade (P  = 0.0002, t-test), ER-negative status (P  =
0.0008), and presence of necrosis (P = 0.025). Nuclear
Jab1 expression was higher in lesions with necrosis (P =
0.026) and exhibited a trend toward higher levels in ER-
negative and high-grade lesions, whereas cytoplasmic
Jab1 was lower in high-grade lesions, but these differences
were not significant and overall Jab1 levels were similar in
all subgroups.
S100A7 expression levels in DCIS correlated positively
with nuclear Jab1 (r = 0.44; P = 0.029, Spearman test) and
inversely with cytoplasmic p27kip1 (r = -0.32; P = 0.028).
When nuclear, cytoplasmic, and total combined expression
o f  J a b 1  w a s  c o n s i d e r e d  r e l a t i v e  t o  S 1 0 0 A 7  s t a t u s ,
S100A7-positive DCIS was associated with higher relative
localization of nuclear Jab1 (P = 0.0019, t-test), but there
was no difference in cytoplasmic or overall Jab1 expression
between S100A7-positive and S100A7-negative DCIS.
Conversely, S100A7-positive DCIS was associated with
significantly lower overall expression of p27kip1  (P  =
0.0168, t-test), and similar but nonsignificant trends toward
lower nuclear and cytoplasmic localization (Figs 1 and 2).
Relationship between S100A7 and progression to 
invasive carcinoma
The entire DCIS series included two categories of DCIS:
cases with and those without associated invasive carci-
noma. When compared with pure DCIS, among DCIS
cases with associated invasive carcinoma there was an
increased proportion that were ER negative, necrosis pos-
itive, and high grade DCIS; this was statistically significant
for the former two factors (P < 0.0001 and P = 0.039,
respectively, χ2 test) but not for grade (P = 0.08). S100A7-
positive cases were also more frequent in DCIS associated
with invasive carcinoma (24/46 [52%]) than in pure DCIS
(39/90 [43%]), but this was not statistically significant.
However, when only high levels of S100A7 were consid-
ered as positive, there was a significantly higher proportion
of S100A7-positive cases among cases of DCIS with
associated invasive carcinoma (10/46 [22%]) than among
pure DCIS cases (5/90 [6%]; p = 0.0037, χ2  test).
Furthermore, the overall S100A7 IHC scores were also
higher in the subgroup of DCIS associated with invasive
components (mean ± standard deviation 51 ± 84) than in
the pure DCIS subgroup (17 ± 45; P = 0.0026, t-test).
In the 46 DCIS cases associated with concurrent invasive
carcinoma, differential S100A7 expression was observed
between in situ and invasive components. S100A7 was
expressed in 25 out of 46 cases. Although it was present
in both the DCIS and invasive components in 14 out of 46
cases, it was limited to the DCIS component in 10 out of
46 cases and to the invasive component in one case. How-
ever, even when expressed in both components, S100A7
expression levels were consistently lower in the invasive
component than in the matching in situ component (P <
0.0001, Wilcoxon test; Fig. 3). In those cases with high
levels of S100A7 expression in DCIS, 10 out of 11 cases
exhibited a 50% or greater reduction in IHC score in the
invasive component. There was no significant change in
Jab1 expression but there was a decrease in p27kip1 cyto-
plasmic expression (P = 0.047) between DCIS and inva-
sive components.
Figure 2
Jab1 and p27kip1 expression relative to S100A7 status Jab1 and p27kip1 expression relative to S100A7 status. (a) The upper 
graph illustrates higher Jab1 nuclear expression (Jab-n) in S100A7-
positive (black columns) than in S100A7-negative (grey columns) 
cases, but similar cytoplasmic (Jab-cyt) and overall expression. (b) The 
lower graph illustrates lower overall p27kip1 expression in S100A7-posi-
tive cases. The columns represent mean immunohistochemistry (IHC) 
scores and bars indicate standard deviations. Significant P values, as 
determined by t-test, are shown.Available online http://breast-cancer-research.com/content/6/4/R308
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S100A7 and recurrence in ductal carcinoma in situ cases 
treated by local excision
Among the 90 patients with pure DCIS, 45 had been
treated by local excision. In this subset, 36 (80%) patients
did not develop a recurrence whereas nine (20%) patients
did develop a recurrence (DCIS in eight and DCIS with an
invasive component in one). There was no significant differ-
ence in patient age, excision margin status, or frequency of
additional radiation or hormonal treatment between the
subgroups with or without recurrence. Similarly, there was
no significant difference between the clinical/pathologic
characteristics of these DCIS cases associated with differ-
ent outcomes, although lesion size could not be accurately
determined and was not included in the analysis. The sub-
set with recurrence exhibited more frequent necrosis (66%
versus 51%) and ER-negative status (44% versus 20%),
and a lower proportion of cases that were treated by radio-
therapy (13% versus 27%); however, none of these differ-
ences was statistically significant. There was also no
significant difference in the frequency of S100A7 expres-
sion between the cases with (4/9 [44%]) and those without
(21/36 [58%]) recurrence.
In seven DCIS cases with recurrence, the tissue blocks
from the recurrence were also available for assessment for
S100A7 expression. Although both nuclear grade and the
presence of necrosis were concordant in only four out of
seven (57%) cases, ER status was concordant in five out
of six (83%) and S100A7 status was concordant in seven
out of seven (100%) cases.
Discussion
The S100 gene family encodes small proteins that share
EF-hand helix-loop-helix domains that are important for their
function as calcium-binding proteins [13]. Several S100
genes are altered in neoplasia and specifically in breast
cancer [14] including S100A4, which can influence the
metastatic phenotype in mammary cell lines and is associ-
ated with poor outcome in invasive breast tumors [15-17].
S100A7 (psoriasin) was first identified as a highly abun-
dant cytoplasmic and secreted protein that is induced in
abnormally differentiating squamous epithelial cells derived
from epidermis of skin affected by psoriasis [18]. This asso-
ciation with psoriasis has suggested a role for S100A7
either in keratinocyte differentiation or as a chemotactic
factor [19-21].
A possible role for S100A7 in breast cancer first emerged
when it was identified as a cDNA that is downregulated in
breast nodal metastasis [22]. We also identified S100A7
as a differentially expressed gene between DCIS and inva-
sive carcinoma [1]. Although previous studies have been
limited to small numbers of DCIS lesions, S100A7 has also
emerged from subtraction hybridization [1], SAGE (serial
analysis of gene expression) [2,23], and proteomic analy-
ses [3] as a highly expressed gene in DCIS. By comparison
S100A7 expression is mostly absent in normal breast tis-
sue, benign, and atypical proliferative ductal lesions [1].
S100A7 is also expressed at a lower frequency in invasive
carcinoma [2,23], where it is associated with markers of
poor prognosis [9] and is an independent prognostic factor
associated with poor outcome in ER-negative tumors [12].
We also recently showed that expression of S100A7 can
promote several features of malignancy in an already inva-
sive ER-negative breast cell line, both in vitro and in vivo
[7].
Taken together, these previous observations support the
hypothesis that S100A7 plays a functional role in breast
tumor progression. In support of a direct role in the devel-
opment of the invasive phenotype, the present study con-
firms that S100A7 is frequently expressed in preinvasive
DCIS and predominantly in DCIS with poor prognostic fac-
tors associated with progression and recurrence [11,24].
As previously shown in other tumors [4] and smaller case
cohorts, S100A7 is also frequently downregulated
between in situ and invasive carcinoma within the same tis-
sue, and high levels of S100A7 expression are more fre-
quent in DCIS associated with invasive carcinoma than in
DCIS without invasion. We also observed that nuclear
S100A7 localization is infrequent in DCIS (21% of positive
cases), which is in contrast to our previous studies of inva-
sive carcinomas in which nuclear S100A7 localization was
more frequent (50% of S100A7-positive cases). The
mechanism that underlies this downregulation and possible
Figure 3
The graph shows levels of S100A7 in matched ductal carcinoma in situ  (DCIS) and invasive (INV) components within the 24 out of 46 cases of  DCIS associated with invasive carcinoma that showed expression in  either component The graph shows levels of S100A7 in matched ductal carcinoma in situ 
(DCIS) and invasive (INV) components within the 24 out of 46 cases of 
DCIS associated with invasive carcinoma that showed expression in 
either component.Breast Cancer Research    Vol 6 No 4    Emberley et al.
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alteration of expression is unknown, but it is unlikely to be
attributable to genomic changes and may reflect changes
in cellular differentiation or response to extracellular stress
signals [2]. However, in the present study we observed that
the overall incidence, as opposed to the level of S100A7
expression, does not necessarily differ significantly
between pure DCIS and DCIS that is associated with inva-
sive carcinoma. This observation supports an alternative
view, namely that S100A7 expression may be more closely
related to specific phenotypic and biologic characteristics
within tumor cells, irrespective of the tumor stage. In sup-
port of this view, although S100A7 has been shown to be
highly expressed in some DCIS lesions [1,23,25] and is
expressed in over 85% of DCIS associated with ER-nega-
tive status and high nuclear grade, it is evident that invasive
tumors within the subset that exhibit these same character-
istics may also express S100A7 at a relatively high fre-
quency (S100A7 was positive in 58% of ER-negative/high-
grade invasive cases in our previous study [12]).
Consideration of these patterns of expression in vivo, com-
bined with a better understanding of the mechanism of
action of S100A7, will help in resolving the role played by
S100A7 in tumor progression. S100A7 may exert an influ-
ence on inflammatory and immune responses, and was sig-
nificantly associated with inflammation in this series of
DCIS cases. However, some S100A7-positive DCIS cases
were not associated with inflammation, and the association
with inflammation is uncertain in skin and invasive breast
tumors [4,12]. Another potential mechanism for a direct
effect of S100A7 within breast cancer cells may involve an
interaction between S100A7 and the multifunctional Jab1
protein [7]. Jab1 was originally identified in mammalian
cells as a factor influencing c-jun mediated transcription of
AP-1 regulated genes [5,26]. It is now known that Jab1 is
a component both of a multimeric protein complex (CSN5
within the CSN/COP9 signalosome) and of the lid unit of
the Ub-26S proteasome [6,27]. Studies in cell lines sug-
gest that Jab1 is involved in diverse interactions with com-
ponents of cell signaling pathways [26,28-34]. Jab1
therefore has the potential to facilitate several aspects of
early tumor progression directly through alteration in multi-
ple cellular properties, which include promoting degrada-
tion of p27kip1 [33].
In studies of human tumors, increased nuclear Jab1 is con-
sistently associated with reduced p27kip1 and has been
associated with poor outcome in some studies of invasive
carcinomas in both breast and ovary, and in lymphoma [35-
37]. However, in a larger cohort of node-negative invasive
breast carcinomas, Jab1 was not related to disease-free
survival [36,38]. This may be consistent with the observa-
tion that Jab1 can affect diverse signaling pathways and
may therefore exert a different influence in subsets of
tumors that depends on the sum and status of these path-
ways. Many of the interactions between Jab1 and signaling
molecules appear to result in translocation of Jab1 from the
cytoplasm to the nucleus in cell lines [7]. We previously
observed that expression of S100A7 induces a relative
increase in nuclear Jab1 in a breast cell line, and a concur-
rent reduction in p27kip1 protein [7]. In the present study we
show that S100A7 expression in DCIS is also associated
with higher nuclear localization of Jab1, without a signifi-
cant increase in overall expression, and with reduced
p27kip1. These findings are consistent with studies that also
found that high nuclear Jab1 localization is inversely corre-
lated with expression of p27kip1 in invasive breast carci-
noma [36,38]. However, unlike S100A7, the frequency of
nuclear Jab1 localization in DCIS was not different
between DCIS and invasive components in this study, and
the expression of Jab1 in DCIS appears to be similar to that
reported in invasive carcinomas, with over 81% of DCIS
exhibiting Jab1 expression in more than 50% of tumor cells
[36]. It is known that many factors apart from S100A7 can
influence Jab1 cellular localization, and future studies will
be needed to determine whether alterations in Jab1 locali-
zation are inherent to any specific stage in breast tumor
progression.
Progression of DCIS may result in recurrence in the form of
DCIS or invasive disease [39]. In this series the majority of
recurrence events were DCIS lesions and we found no
relationship with S100A7 expression. Recurrence in the
form of DCIS may be derived from residual disease attrib-
utable to incomplete surgery of the original focus of dis-
ease, from emergence of distant lesions in an originally
multifocal disease, or de novo disease arising in previously
normal remaining tissue. Molecular studies suggest that the
former may often occur [39,40]. Our finding that the
S100A7 phenotype is reliably conserved between primary
lesions and recurrences is also consistent with this view.
Conclusion
Although the number of cases that were treated by local
resection or that developed invasive recurrence is small
and limits firm conclusions, our findings suggest that
S100A7 does not influence recurrence of DCIS. Similarly,
the finding of comparable incidence of S100A7 expression
in both pure DCIS and DCIS associated with invasive car-
cinoma does not support an essential role in invasion. How-
ever, the association of S100A7 with established poor
prognostic factors and higher levels of expression in DCIS
associated with invasive components are consistent with a
role in facilitating progression. Our findings also further
support an association between S100A7 and Jab1, and
the view that this interaction is potentially important in influ-
encing cell signaling and mediating tumor progression.
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